4 recruiting. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Follicular Lymphoma ( FL): new trials by email Literature Review of Follicular Lymphoma ( FL) trials Research Report on Follicular Lymphoma ( FL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor) - Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 30 | 2025-09-15 | 2026-01-21 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| Zanubrutinib Combined With G-CVP in Previously Untreated FL zanubrutinib, obinutuzumab,combined with CVP - Follicular Lymphoma ( FL) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2025-01-01 | 2025-05-07 |
Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (2) · Burkitt Lymphoma (1) · Cytokine Release Syndrome (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma, Non-Hodgkin (3) · Disease Attributes (2) · Lymphoma, B-Cell (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
COP protocol 2 (1) · Immune Checkpoint Inhibitors (1) · Therapeutics (1) · obinutuzumab (1) · relmacabtagene autoleucel (1) · sintilimab (1) · zanubrutinib (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Health Institutes of Turkey (1) · Sun Yat-sen University (1)
China (3) · Turkey (Türkiye) (1)